Wednesday, July 8, 2026

biotech · Lymphoma, Non-Hodgkin · Systemic Lupus Erythematosus · CRBU

Caribou Biosciences

Caribou Biosciences clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Berkeley, USA HQ
2012 Founded
131 Employees
Public company Type
CRBU · NYSE Ticker
Company details
Status
Public
HQ
Berkeley, USA
Founded
2012
Employees
131
Programs
4
Drugs
2
Patents
19
Intelligence · Clinical Programs

Caribou Biosciences projects

4 ClinicalTrials.gov programs sponsored by Caribou Biosciences.

Caribou Biosciences has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial
  2. CB-010

    Caribou Biosciences

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial
  3. CB-011

    Caribou Biosciences

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial
  4. CB-012

    Caribou Biosciences

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Caribou Biosciences have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.